Valuation: Cytori Therapeutics Inc

Market Cap 53.64L 48.92L 45.23L 40.82L 76.88L 50Cr 79.91L 5.46Cr 2.16Cr 27Cr 2.01Cr 1.97Cr 85Cr P/E 2026 *
-0.16x
P/E 2027 * -0.19x
Enterprise Value 53.64L 48.92L 45.23L 40.82L 76.88L 50Cr 79.91L 5.46Cr 2.16Cr 27Cr 2.01Cr 1.97Cr 85Cr EV / Sales 2026 *
1.33x
EV / Sales 2027 * 0.39x
Free-Float
75.98%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 64 02/04/2014
Director of Finance/CFO 52 06/02/2020
Chief Operating Officer 53 06/11/2026
Director TitleAgeSince
Director/Board Member 64 01/10/2002
Chairman 77 25/01/2018
Director/Board Member 66 01/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.34%-3.09%+56.10%+68.83% 6.55TCr
-0.95%-3.93%+6.82%+88.99% 5.89TCr
+0.62%+0.63%+26.55%+87.63% 5.52TCr
-2.34%-3.90%+10.90%+115.97% 4.61TCr
+0.09%-6.08%+18.67%+25.90% 4.25TCr
-2.58%+0.24%+18.54%+41.28% 3.56TCr
-1.76%-11.56%+126.44%+649.27% 3.46TCr
-0.04%-0.93%+76.71%+57.52% 3.25TCr
-1.69%-0.79%-40.58%+382.68% 2.63TCr
Average -1.08%-3.40%+33.35%+168.67% 4TCr
Weighted average by Cap. -1.01%-3.29%+33.47%+143.23%

Financials

2026 *2027 *
Net sales 40.41L 36.85L 34.07L 30.75L 57.92L 38Cr 60.2L 4.12Cr 1.63Cr 20Cr 1.52Cr 1.48Cr 64Cr 1.38Cr 1.26Cr 1.17Cr 1.05Cr 1.98Cr 129.41Cr 2.06Cr 14Cr 5.58Cr 70Cr 5.2Cr 5.09Cr 220.57Cr
Net income -3.17Cr -2.89Cr -2.67Cr -2.41Cr -4.54Cr -295.98Cr -4.72Cr -32Cr -13Cr -159.76Cr -12Cr -12Cr -504.47Cr -2.97Cr -2.71Cr -2.5Cr -2.26Cr -4.25Cr -277.17Cr -4.42Cr -30Cr -12Cr -149.61Cr -11Cr -11Cr -472.41Cr
Net Debt - -
Logo Cytori Therapeutics Inc
Cerenome, Inc., formerly Plus Therapeutics, Inc., is a healthcare company. The Company is focused on central nervous system (CNS) cancers through three business areas: precision diagnostics, targeted radiopharmaceutical therapeutics, and proprietary data analytics. Its subsidiary CNSide Diagnostics, LLC, develops and commercializes proprietary laboratory-developed tests, including the CNSide cerebrospinal fluid (CSF) assay platform, designed to identify, characterize and monitor tumor cells in patients with CNS cancers. Its lead product candidate, rhenium (186Re) obisbemeda (REYOBIQ), is designed for CNS cancers, including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC), through direct localized delivery utilizing tissue access methods, including convection-enhanced delivery (CED) and others. Its Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat primary and metastatic solid organ cancers.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cytori Therapeutics Inc